SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)

BIOLOGICAL2 trials

Sponsors

Novavax

Conditions

COVID-19Covid19SARS-CoV Infection

Phase 2

Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

CompletedNCT05468736

NovavaxCOVID-19

Start: 2022-07-22End: 2025-10-25Updated: 2026-05-22

Phase 3

A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2

CompletedNCT04611802

NovavaxCovid19, SARS-CoV Infection

Start: 2020-12-27End: 2023-12-15Updated: 2023-12-21

Related Papers

Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19).

2025-06-05

P-1972. SARS-CoV-2 Vaccine–Induced IgG4 Response Negatively Correlates with Neutralizing Antibodies and Fc Effector Functions

Open Forum Infectious Diseases2025-01-29

Vaccine efficacy of NVX-CoV2373 against SARS-CoV-2 infection in adolescents in the USA: an ancillary study to a phase 3, observer-blinded, randomised, placebo-controlled trial.

2025-01-272 citations

Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials

The Journal of Infectious Diseases2024-09-037 citations

Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials

UNC Libraries2024-06-21

Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials.

2023-06-235 citations

Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents

JAMA Network Open2023-04-2648 citations

Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial.

2023-01-1985 citations

LB746. Safety and Immunogenicity of a Booster Dose of Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) in Adults from the PREVENT-19 Trial in the United States

Open Forum Infectious Diseases2022-12-012 citations

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico

New England Journal of Medicine2021-12-15444 citations

Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial

PLoS Medicine2021-10-01112 citations